CMG Global Holdings LLC Decreases Stock Position in Eli Lilly and Company $LLY

CMG Global Holdings LLC lowered its position in shares of Eli Lilly and Company (NYSE:LLY) by 1.2% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,682 shares of the company’s stock after selling 44 shares during the period. Eli Lilly and Company makes up about 1.6% of CMG Global Holdings LLC’s investment portfolio, making the stock its 18th largest position. CMG Global Holdings LLC’s holdings in Eli Lilly and Company were worth $2,975,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. WestEnd Advisors LLC grew its stake in shares of Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Eli Lilly and Company in the first quarter valued at about $27,000. Citizens National Bank Trust Department boosted its holdings in Eli Lilly and Company by 180.0% in the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC increased its holdings in Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after purchasing an additional 31 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on LLY. Weiss Ratings reiterated a “hold (c+)” rating on shares of Eli Lilly and Company in a research note on Wednesday, October 8th. UBS Group reduced their price objective on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Daiwa Capital Markets lowered shares of Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 target price on the stock. in a research note on Sunday, August 17th. Finally, Cantor Fitzgerald set a $925.00 price target on shares of Eli Lilly and Company and gave the stock an “overweight” rating in a research report on Thursday, October 9th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $939.12.

Insider Buying and Selling at Eli Lilly and Company

In related news, EVP Daniel Skovronsky bought 1,000 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president owned 137,660 shares of the company’s stock, valued at $87,331,504. This represents a 0.73% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of Eli Lilly and Company stock in a transaction dated Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, with a total value of $75,018.06. Following the acquisition, the director owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders acquired 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.14% of the company’s stock.

Eli Lilly and Company Stock Down 1.9%

Shares of NYSE:LLY opened at $803.53 on Monday. The company’s fifty day moving average is $753.09 and its two-hundred day moving average is $765.70. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $935.63. The stock has a market capitalization of $760.51 billion, a price-to-earnings ratio of 52.52, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts’ consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company’s revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.